tbuckley/cabot-search huggingface dataset:
DNA repair suppression and effect of cisplatin in mesothelioma and lung cancer cell lines.
Authors: Oluf D. Røe, Wu Chen, Xiaofei Zhi, Duan Chen, Yijiang Chen
Journal: Journal of Clinical Oncology (2013)

e13542 Background: Recently we characterized a gene profile with overexpressed DNA double strand repair systems in mesothelioma versus normal tissue, where homologous recombination (HR) and non-homologous end joining (NHEJ) were prominent systems overexpressed. They play a role in resistance to the DNA damaging agent cisplatin, the backbone of both mesothelioma and lung cancer treatment. We hypothesized that inhibition of these systems could increase the effect of cisplatin. Methods: Cisplatin and two natural compounds A and B inhibiting HR and NHEJ respectively were tested as single treatment and various combinations in mesothelioma (MSTO-211H), parental (A549) and cisplatin resistant lung cancer cells (A549/DDP) were the dose-response and time-response was determined. Sterile MTT (0.5mg/ml) was added at 37°C for 4h, then removed and DMSO added for 10 minutes. Spectrometric absorbance at 570nm was measured. The inhibition rate was calculated by the relative inhibition curve. The IC30 doses of cisplatin was combined with IC5 of the experimental compounds to reveal the effects of combining chemotherapy with non-toxic compounds. Results: The IC5 of the experimental compounds A and B were 2μM and 1mM in the MSTO-211H and A549 respectively, and similarly in the A549/DDP cells, 2μM and 0.5mM. The IC30 of cisplatin was 1,5 μg/ml in the MSTO and A549 and 20 μg/ml (13-fold) in the A549/DDP cells.The combination of IC5 of A and B without cisplatin showed a synergic effect of about 50%. IC30 of cisplatin from 24h to 72h without pretreatment showed 20% inhibition at 48h and interestingly the inhibition rate was reduced to 10% at 72h. Pretreatment with A and B for 24h, and then cisplatin for 48h had the same effect as cisplatin together with A and B for 48h, about 30% inhibition. Pretreatment with A and B for 24h, then addition of cisplatin plus A and B for 48h had the strongest effect of &gt;50% inhibition rate. Conclusions: Our results indicate that suppression of HR and NHEJ in both mesothelioma and non-small cell lung cancer cell lines by non-toxic doses increased cisplatin efficacy. The acquired cisplatin resistant A549/DDP remained sensitive to the natural inhibitors. Molecular analyses on DNA damage and apoptosis will be presented at the meeting.
The Need for Standardized Methods for Measuring the Aorta
Authors: Federico M. Asch, Eugene Yuriditsky, Siddharth K. Prakash, Mary J. Roman, Jonathan W. Weinsaft, Gaby Weissman, Wm. Guy Weigold, Shaine A. Morris, William J. Ravekes, Kathryn W. Holmes, Michael Silberbach, Rita K. Milewski, Barbara L. Kroner, Ryan Whitworth, Kim A. Eagle, Richard B. Devereux, Neil J. Weissman
Journal: JACC. Cardiovascular imaging (2016)
Abstract 17591: New Methods to Display and Summarize Late Reintervention Outcomes, Follow-Up and Vital Status Information After Surgery for Atrial Fibrillation
Authors: Adin-Cristian Andrei, Patrick M McCarthy, Richard Lee, Edwin C McGee, S. Christopher Malaisrie, Jane Kruse, Brittany R Lapin, Hugh Calkins
Journal: Circulation (2012)

Background: There are limited statistical methods to display certain clinically important interventions in patients that undergo catheter ablation (CA) or cardioversion (CV) after surgical ablation of atrial fibrillation (SAAF). Current reporting is limited to yearly or last follow-up summaries and does not convey the outcome dynamics over time. Following a recommendation of the 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and SAAF to develop new robust outcome reporting methods, we propose a comprehensive measure of the overall burden of reintervention after SAAF. Methods: 729 patients (60% males, age 67±12 yrs, follow-up 3.3±1.9 yrs, 92% 1-yr survival) underwent SAAF with or without concomitant cardiac surgery between 04/04 and 12/10. Of them, N=141 patients had a total of R=232 late reinterventions grouped as follows: (a) CAs alone (N=21, R=24), (b) CVs alone (N=87, R=111), (c) at least a CA and a CV (N=33, R=97). As a robust reporting measure, we propose the mean cumulative number MCF(t) ...
Interventions for hirsutism excluding laser and photoepilation therapy alone: abridged Cochrane systematic review including<scp>GRADE</scp>assessments
Authors: E.J. Zuuren, Z. Fedorowicz
Journal: British Journal of Dermatology (2016)

Hirsutism is a common disorder with a major impact on quality of life. The most frequent cause is polycystic ovary syndrome. Effects of interventions (except laser and light‐based therapies) were evaluated, including Grading of Recommendations Assessment, Development and Evaluation assessments. Searches included Cochrane Skin Group Specialised Register, CENTRAL in The Cochrane Library, Medline, Embase and five trials registers to June 2014. We included 157 randomized controlled trials (RCTs) with 10 550 participants. The majority were assessed as having a 'high risk' of bias (123 of 157). The quality of evidence was rated moderate to very low for most outcomes. Pooled data for an oral contraceptive (OCP) (ethinyl oestradiol and cyproterone acetate) compared with another OCP (ethinyl oestradiol and desogestrel) demonstrated that both treatments were effective in reducing Ferriman–Gallwey scores, but the mean difference (MD) was not statistically significant [−1·84, 95% confidence interval (CI): −3·86–0·18]. Flutamide was more effective than placebo in two studies (MD −7·60, 95% CI: −10·53 to −4·67 and MD −7·20, 95% CI: −10·15 to −4·25), as was spironolactone (MD −7·69, 95% CI: −10·12 to −5·26). Spironolactone appeared to be as effective as flutamide (two studies) and finasteride (two studies). However, finasteride and the gonadotropin‐releasing analogues showed discrepant results in several RCTs. Metformin was ineffective. Cyproterone acetate combined with OCPs demonstrated greater reductions in Ferriman–Gallwey scores. Lifestyle interventions reduced body mass index but did not show improvement in hirsutism, and although cosmetic measures are frequently used, no RCTs investigating cosmetic treatments were identified. RCTs investigating OCPs in combination with antiandrogens or finasteride vs. OCP alone, or the different antiandrogens and 5α‐reductase inhibitors are warranted.
Finerenone for Albuminuria in Patients With Diabetic Nephropathy
Authors: Yanhuan Feng, Xiaoxi Zeng, Ping Fu
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Xenotropic retrovirus Bxv1 in human pancreatic β cell lines
Authors: Jeannette S. Kirkegaard, Philippe Ravassard, Signe Ingvarsen, Marc Diedisheim, Emilie Bricout-Neveu, Mads Grønborg, Thomas Frogne, Raphael Scharfmann, Ole D. Madsen, Claude Rescan, Olivier Albagli
Journal: Journal of Clinical Investigation (2016)

It has been reported that endogenous retroviruses can contaminate human cell lines that have been passaged as xenotransplants in immunocompromised mice. We previously developed and described 2 human pancreatic β cell lines (EndoC-βH1 and EndoC-βH2) that were generated in this way. Here, we have shown that B10 xenotropic virus 1 (Bxv1), a xenotropic endogenous murine leukemia virus (MuLV), is present in these 2 recently described cell lines. We determined that Bxv1 was also present in SCID mice that were used for in vivo propagation of EndoC-βH1/2 cells, suggesting that contamination occurred during xenotransplantation. EndoC-βH1/2 cells released Bxv1 particles that propagated to human 293T and Mus dunni cells. Mobilization assays demonstrated that Bxv1 transcomplements defective MuLV-based retrovectors. In contrast, common rodent β cell lines, rat INS-1E and RIN-5F cells and mouse MIN6 and βTC3 cells, displayed either no or extremely weak xenotropic helper activity toward MuLV-based retrovectors, although xenotropic retrovirus sequences and transcripts were detected in both mouse cell lines. Bxv1 propagation from EndoC-βH1/2 to 293T cells occurred only under optimized conditions and was overall poorly efficient. Thus, although our data imply that MuLV-based retrovectors should be cautiously used in EndoC-βH1/2 cells, our results indicate that an involuntary propagation of Bxv1 from these cells can be easily avoided with good laboratory practices.
Safety, kinetics, and outcome following rituximab (R) in combination with FAB chemotherapy in children and adolescents (C+A) with stage III/IV (Group B) and BM+/CNS+ (Group C) mature B-NHL: A Children's Oncology Group report.
Authors: M. S. Cairo, J. C. Lynch, L. Harrison, S. L. Perkins, B. Shiramizu, T. G. Gross, W. Sanger, S. Goldman
Journal: Journal of Clinical Oncology (2010)

9536 Background: During the FAB96 trial, we demonstrated that therapy could be reduced in C+A with Stage III/IV B-NHL (Arm B4) (2 yr EFS of 84%) (Patte/Cairo et all, Blood, 2007) however, no reduction in therapy was possible in GP C pts (2 yr EFS of 79±2.7%) (Cairo/Patte et al, Blood, 2007). R has been demonstrated to increase EFS and OS in adults with DLBCL (Coiffier et al, NEJM, 2002, Pfreundschuh et al, Lancet Oncology, 2006).The objective of the study was to determine the safety, kinetics and outcome following R in combination with FAB chemotherapy in C+A with mature B-NHL. Methods: R (375 mg/m2/dose), supplied by Genentech, was administered on days -2 and 0 of COPADM 1 + 2 and day 0 of CYM 1+2 and CYVE 1+2 of FAB B4 and C1 chemotherapy (6 doses). Pts on subpilot received the same except for day -2 and 0 of COPADM1 (4 doses). R levels were measured by Elisa (polyclonal goat anti-R conjugated to horse radish peroxidase) (detection limit of 0.5 mcg/ml). Levels were measured 1 hour prior to R, 30-60' after R in COPADM1+2 and 1, 3, 6, and 9 mo after the last R. HACA to R was also determined. Results: There were 48 and 42 pts with GP B and C mature B-NHL registered. Following 274 and 237 R infusions in GP B+C patients, respectively, no SAE was probably or directly attributed to R and no HACA formation. A total of 28 and 16 pts had R PK samples taken. Peak R levels after first and second dose were 207±9 (mean±SEM) and 294±19 μ g/ml (GP B) and 181±10 and 236±33 μ g/ml (GP C), while R trough levels after first dose and prior to COPADM 2 were 133±9 and 122±31 μ g/ml (GP B) and 132±26 and 51±8 μ g/ml (GP C), respectively. R levels of combined GP B+C pts at 1, 3, 6, and 9 mo post last R were 67.0±5.6, 15.8±1.9, 2.29±0.44, and 1.27±0.44 μ g/ml, respectively, resulting in a t1/2 of 27.8±1.7 days. The 2 yr EFS and OS for stage III/IV GP B and BM+/CNS+ GP C pts was 93% and 96%,and 86% and 88%, respectively, Two toxic deaths (GP C) (Aspergillosis pneumonia [1] and typhlitis [1]). Conclusions: R can be safely administered with the FAB chemotherapy B4 and C1 resulting in R peak and trough levels and an estimated R t1/2 that are similar to adults. The long-term EFS and OS is excellent in C+A with advanced mature B-NHL. No significant financial relationships to disclose.
Addition of etoposide to CHOP chemotherapy in untreated patients with high-grade non-Hodgkin’s lymphoma
Authors: F. Celsing, S. Widell, K. Merk, P. Bernell, G. Grimfors, A. Hedlund, J. Liliemark, E. Svedmyr, E. Ösby, M. Björkholm
Journal: Annals of Oncology (1998)
The cytotoxicity of combined paricalcitol, docetaxel and radiation in head and neck squamous cell carcinoma
Authors: T. W. Huang, S. Northrup
Journal: Journal of Clinical Oncology (2006)

15526 Background: Paricalcitol is a calcitriol analog used in the treatment of secondary hyperparathyroidism. It produces less hypercalcemia compared to calcitriol and has low clinical toxicity. We have shown previously that paricalcitol is antiproliferative in head and neck squamous cell carcinomas (HNSCC) in vitro. However, its interaction in combination with docetaxel and radiation has not been elucidated. The purpose of this study is to evaluate the combined effects of paricalcitol, docetaxel, and radiation in vitro in SCC-15 cells, a human tongue squamous cell carcinoma cell line. Methods: The cytotoxic effects were assessed using MTT assays. SCC 15 cells were plated, allowed to attach for 24 hours, and then treated with paricalcitol at 0, 12.5, 25, or 50 nM. After 24 hours, docetaxel at 0, 0.05, 0.15, or 0.3 nM was applied, followed in 24 hours by single treatment with radiation at 0, 2, 4, or 6 Gy. MTT assays were performed after incubation for 5 days. CalcuSyn analysis was used to determine if the interaction between paricalcitol, docetaxel, and radiation is synergistic, additive, or antagonistic. Results: Paricalcitol alone at 12.5, 24, and 50 nM produced growth inhibition of 30, 38, and 40%, respectively. Docetaxel alone at 0.05, 0.15, and 0.3 nM resulted in 33, 61, and 72% growth inhibition, respectively. Radiation at 2, 4, and 6 Gy produced 44, 57, and 62% inhibition, respectively. Sequential paricalcitol and docetaxel at the concentrations tested followed by 2 Gy radiation produced additive to synergistic cytotoxicity. Antagonism was seen with 4 Gy and all combinations of paricalcitol and docetaxel. Antagonism was also seen with 6 Gy and 0.15 or 0.3 nM of docetaxel. Conclusions: Sequential application of paricalcitol, docetaxel, and then radiation at moderate doses produced additive to synergistic cytotoxicity in SCC-15 cells. The results of this study provide support for further investigations of combined paricalcitol, docetaxel and radiation therapy in the treatment of head and neck cancers. [Table: see text]
Models for cognition and emotion: Evolutionary and linguistic considerations
Authors: Carlos Montemayor
Journal: Behavioral and Brain Sciences (2015)

Abstract A central claim in Luiz Pessoa's (2013) book is that the terms “emotion” and “cognition” can be useful in characterizing behaviors but will not be cleanly mapped into brain regions. In order to be verified, this claim requires models for the integration and interfacing of emotion and cognition; yet, such models remain problematic.
Association Between Indoor Tanning and Melanoma in Younger Men and Women
Authors: DeAnn Lazovich, Rachel Isaksson Vogel, Martin A. Weinstock, Heather H. Nelson, Rehana L. Ahmed, Marianne Berwick
Journal: JAMA Dermatology (2016)

In the United States and Minnesota, melanoma incidence is rising more steeply among women than men younger than 50 years. To our knowledge, no study has examined age- and sex-specific associations between indoor tanning and melanoma to determine if these trends could be due to greater indoor tanning use among younger women.
Metabolic control analysis and enzyme variation: nutritional manipulation of the flux from ethanol to lipids in Drosophila.
Authors: P W Heinstra, B W Geer
Journal: Molecular Biology and Evolution (1991)

The effect that variation in activities of the enzymes alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) has on the flux from 14C-ethanol to lipids was examined in third-instar larvae of Drosophila melanogaster and D. simulans. The activities of ADH and ALDH were also nutritionally manipulated by the inhibitor, cyanamide. Feeding larvae cyanamide before the flux test eliminated greater than 98% of the ALDH activity but only 40% of the ADH activity. The mean +/- SD flux control coefficient for ADH activity was 0.86 +/- 0.12, and that for ALDH activity was 0.02 +/- 0.07. This suggests that ADH is the major rate-limiting enzyme for the ethanol-to-lipid pathway in Drosophila larvae under the current experimental conditions.
Clinical guidelines and indications for bronchoalveolar lavage (BAL): pulmonary malignancies
Authors: SI Rennard, C Albera, L Carratu, W Bauer, H Eckert, J Linder, M Pirozynski, AJ Robalo-Cordeiro, C Sanguinetti, G Semenzato, al. et
Journal: European Respiratory Journal (1990)
Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease
Authors: Aurelien Amiot, Jean-Charles Grimaud, Laurent Peyrin-Biroulet, Jerome Filippi, Benjamin Pariente, Xavier Roblin, Anthony Buisson, Carmen Stefanescu, Caroline Trang-Poisson, Romain Altwegg, Philippe Marteau, Thibaud Vaysse, Anne Bourrier, Stephane Nancey, David Laharie, Matthieu Allez, Guillaume Savoye, Jacques Moreau, Charlotte Gagniere, Lucine Vuitton, Stephanie Viennot, Alexandre Aubourg, Anne-Laure Pelletier, Guillaume Bouguen, Vered Abitbol, Yoram Bouhnik, Aurelien Amiot, Charlotte Gagniere, Jean-Charles Grimaud, Laurent Peyrin-Biroulet, Camille Zallot, Marc-Andre Bigard, Jerome Filippi, Xavier Hebuterne, Benjamin Pariente, Maria Nachury, Pierre Desreumaux, Xavier Roblin, Emilie Del Tedesco, Anthony Buisson, Gilles Bommelaer, Carmen Stefanescu, Arnaud Boureille, Caroline Trang-Poisson, Romain Altwegg, Philippe Marteau, Xavier Dray, Franck Carbonnel, Philippe Seksik, Laurent Beaugerie, Jacques Cosnes, Harry Sokol, Cecilia Landman, Stephane Nancey, Gilles Boschetti, David Laharie, Florian Poullenot, Matthieu Allez, Jean-Marc Gornet, Clautilde Baudry, Guillaume Savoye, Jacques Moreau, Charlotte Gagniere, Lucine Vuitton, Stephane Koch, Stephanie Viennot, Alexandre Aubourg, Laurence Picon, Anne-Laure Pelletier, Gaelle Sickersen, Guillaume Bouguen, Vered Abitbol, Stanislas Chaussade, Yoram Bouhnik, Stephane Nahon, Betsy Winkfield, Hedia Brixi-Benmansour, Rodica Gincul, Jean-Christophe Barberis, Bruno Bonaz, Christophe Michiels, Franck Zerbib, Marie Bourrier de Beauregard, Christophe Locher, Sophie Davin-Couve, Armelle Poirette, Laurence Guillem, Monica Stetiu-Mocanu, Sylvain Beorchia, Jawad Al Qaddi
Journal: Clinical Gastroenterology and Hepatology (2016)
A randomized controlled study comparing CMF plus TAM with UFT plus TAM as postoperative adjuvant therapy in women with node-positive breast cancer
Authors: H. Inaji, Y. Park, K. Okamura, S. Mitsuyama, T. Saito, J. Koh, S. Kyono, K. Higaki, H. Koyama, T. Suzuki
Journal: Journal of Clinical Oncology (2004)

586 Background: The response rate of UFT in advanced or recurrent breast cancer is similar to that of CMF (UFT: 39.3%, CMF: 36.1%), and relapse-free survival is similar for these treatments when given as postoperative adjuvant therapy (odds reduction, UFT: 21.0%, CMF: 23.5%). Methods: We conducted a randomized controlled study to compare the effectiveness and toxicity of CMF plus TAM (treatment M) with that of UFT plus TAM (treatment U) in women with Stage I, II, and IIIA node-positive breast cancer. Treatment M comprised 6 cycles of CMF therapy [CPA 65 mg/m2 (po): days 1–14, MTX 40 mg/m2 (iv): days 1 and 8, 5-FU 500 mg/m2 (iv): days 1 and 8] plus TAM 20 mg/day (po) for 2 years. Treatment U comprised UFT 270 mg/m2 /day(po) plus TAM 20 mg/day (po), both given for 2 years. Results: Between September 1996 and July 2000 a total of 377 patients were enrolled; 350 patients (92.8%) who met the eligibility criteria and started treatment according to protocol were included in analysis. There was no difference between the groups in any major clinical characteristic. At 3 years the relapse-free survival rate was 82.4% with treatment M and 81.8% with treatment U (log-rank test: p=0.92), and the overall survival rate was 93.9% with treatment M and 93.3% with treatment U (log-rank test: p=0.81). These differences were not significant. Toxicity occurring in more than 20% of patients were leukopenia, elevation of GOT, elevation of GPT, anorexia, nausea/vomiting, and hair loss in the patients given treatment M and elevation of GOT, elevation of GPT in those given treatment U. The incidences of leukopenia, anorexia, nausea/vomiting, and hair loss were lower with treatment U than with treatment M. Conclusions: The combination of UFT plus TAM is a promising regimen for postoperative adjuvant chemotherapy in women with node-positive breast cancer. No significant financial relationships to disclose.
Seasonality of symptoms in women with late luteal phase dysphoric disorder
Authors: D D Maskall, R W Lam, S Misri, D Carter, A J Kuan, L N Yatham, A P Zis
Journal: American Journal of Psychiatry (1997)

Objective: Both late luteal phase dysphoric disorder (LLPDD) and seasonal affective disorder are cyclical disorders often manifested by "atypical" depressive features.The goal of this study was to determine whether patients with LLPDD demonstrate substantial seasonal variation in symptoms.Method: Consecutive female patients attending a subspecialty clinic in a university teaching hospital were assessed by means of DSM-III-R criteria.All subjects completed the Seasonal Pattern Assessment Questionnaire, modified to include items on the seasonality of premenstrual symptoms.The results were compared with those of a group of female nonclinical subjects (N=50).Results: One hundred patients met the DSM-III-R criteria for LLPDD.Compared to the nonclinical group, the LLPDD patients had a significantly higher mean global seasonality score (an index of seasonality of mood and vegetative symptoms) and a significantly higher rate of seasonal affective disorder (38% versus 8%) as determined by Seasonal Pattern Assessment Questionnaire criteria.Twenty-five percent of the LLPDD group rated their seasonal variation in premenstrual symptoms as marked or severe, while 30% considered seasonal changes in overall symptoms to be a marked or severe problem.Conclusions: These results suggest that patients with LLPDD have substantial seasonal patterns in mood and premenstrual symptoms.These seasonal patterns have implications for the clinical assessment and treatment of LLPDD.For example, light therapy may be beneficial for women with seasonal worsening of LLPDD.
Imaging findings of mimickers of hepatocellular carcinoma
Authors: Tae Kyoung Kim, Eunchae Lee, Hyun-Jung Jang
Journal: Clinical and Molecular Hepatology (2015)

Radiological imaging plays a crucial role in the diagnosis of hepatocellular carcinoma (HCC) as the noninvasive diagnosis of HCC in high-risk patients by typical imaging findings alone is widely adopted in major practice guidelines for HCC. While imaging techniques have markedly improved in detecting small liver lesions, they often detect incidental benign liver lesions and non-hepatocellular malignancy that can be misdiagnosed as HCC. The most common mimicker of HCC in cirrhotic liver is nontumorous arterioportal shunts that are seen as focal hypervascular liver lesions on dynamic contrast-enhanced cross-sectional imaging. Rapidly enhancing hemangiomas can be easily misdiagnosed as HCC especially on MR imaging with liver-specific contrast agent. Focal inflammatory liver lesions mimic HCC by demonstrating arterial-phase hypervascularity and subsequent washout on dynamic contrast-enhanced imaging. It is important to recognize the suggestive imaging findings for intrahepatic cholangiocarcinoma (CC) as the management of CC is largely different from that of HCC. There are other benign mimickers of HCC such as angiomyolipomas and focal nodular hyperplasia-like nodules. Recognition of their typical imaging findings can reduce false-positive HCC diagnosis. Keywords: Carcinoma, Hepatocellular; Liver; Diagnostic imaging; Benign neoplasms